BACKGROUND: Epidemiological studies have reported associations between air pollution exposure and increases in cardiovascular morbidity and mortality. Exposure to air pollutants can influence cardiac autonomic tone and reduce heart rate variability, and may increase the risk of cardiac arrhythmias, particularly in susceptible patient groups.

OBJECTIVES: We investigated the incidence of cardiac arrhythmias during and after controlled exposure to air pollutants in healthy volunteers and patients with coronary heart disease.

METHODS: We analyzed data from 13 double-blind randomized crossover studies including 282 participants (140 healthy volunteers and 142 patients with stable coronary heart disease) from whom continuous electrocardiograms were available. The incidence of cardiac arrhythmias was recorded for each exposure and study population.

RESULTS: There were no increases in any cardiac arrhythmia during or after exposure to dilute diesel exhaust, wood smoke, ozone, concentrated ambient particles, engineered carbon nanoparticles, or high ambient levels of air pollution in either healthy volunteers or patients with coronary heart disease.

CONCLUSIONS: Acute controlled exposure to air pollutants did not increase the short-term risk of arrhythmia in participants. Research employing these techniques remains crucial in identifying the important pathophysiological pathways involved in the adverse effects of air pollution, and is vital to inform environmental and public health policy decisions.

Citation: Langrish JP, Watts SJ, Hunter AJ, Shah AS, Bosson JA, Unosson J, Barath S, Lundbäck M, Casse FR, Donaldson K, Sandström T, Blomberg A, Newby DE, Mills NL. 2014. Controlled exposure to air pollutants and risk of cardiac arrhythmia. Environ Health Perspect 122:747–753; http://dx.doi.org/10.1289/ehp.1307337

Introduction

Exposure to air pollution is a major public health concern and is associated with morbidity and mortality from cardiorespiratory diseases (Brook et al. 2010). Indeed, on a population level, exposure to combustion-derived particulate air pollution from traffic is recognized as a major trigger for myocardial infarction (Nawrot et al. 2011). With growing concern over the effects of exposure to air pollutants for the general public and susceptible patient populations, there is an increasing interest in defining the risks and underlying vascular and inflammatory mechanisms that may explain these observed associations.

The cardiovascular effects of air pollution are complex and include effects on vascular endothelial function, thrombosis, platelet function, and atherogenesis, as well as changes in blood pressure and cardiac autonomic control (Langrish et al. 2012a). Indeed, changes in autonomic control of the heart, measured by heart rate variability (HRV), have been widely studied in the air pollution literature, and a recent meta-analysis of 18,667 participants enrolled in 29 studies reported an inverse relationship between measures of HRV and exposure to particulate air pollution (Pieters et al. 2012). Reduced HRV represents a withdrawal of cardiac vagal tone or an increase in sympathetic tone and is a predictor of poor prognosis in patients recovering from myocardial infarction and patients with cardiac failure (Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology 1996) and may increase the risk of cardiac arrhythmias in these at-risk patients (Odemuyiwa et al. 1991). Recent evidence has linked activity of the autonomic nervous system and atrial electrical properties with the triggering of atrial arrhythmias such as atrial fibrillation (AF) and flutter (Arora 2012; Lo et al. 2011; Park et al. 2012). There is some limited epidemiological evidence linking exposure to air pollutants to both ventricular and supraventricular arrhythmias (Brook et al. 2010), although these associations are not consistent (Gold and Mittelman 2013).

In the present study, we explored our database of continuous electrocardiographic (ECG) recordings made during controlled exposures to a range of air pollutants to determine whether there is evidence of an increase in the short-term risk of arrhythmia during such exposures.

Methods

Data were extracted from 13 consecutive randomized double-blind crossover studies including healthy volunteers and patients with coronary heart disease from 2004 to 2013 (Table 1). All trials were reviewed and approved by the appropriate local ethics review boards of the NHS Research Ethics Service (Edinburgh, UK), Umeå University (Umeå, Sweden), or the Chinese Academy of Medical Sciences (Beijing, China). All participants gave written informed consent in accordance with the Declaration of Helsinki. All healthy volunteers had a normal 12-lead ECG and cardiovascular response to exercise determined at screening. Patients with coronary heart disease were excluded if they had a history of arrhythmia, severe coronary disease without revascularization, significant valvular heart disease or left ventricular systolic dysfunction, conduction abnormality on a resting 12-lead ECG, uncontrolled hypertension, or an acute coronary syndrome within the previous 3 months. Participants were exposed to a variety of air pollutants in controlled-exposure studies or in ambient settings [with the use of a highly efficient facemask to provide a control (Langrish et al. 2009)]. Detailed monitoring of personal exposure was performed and continuous ECGs recorded to allow for the assessment of
cardiac arrhythmia (Barath et al. 2010; Cruts et al. 2009, 2012b; Mills et al. 2005, 2007, 2008, 2011b).

In controlled-exposure studies, participants were exposed using a randomized, double-blind controlled crossover design to either filtered air or to the experimental pollutant during intermittent exercise. The exposure time varied across these studies and is documented below. Each study visit was separated from the next by at least 7 days.

**Controlled and ambient exposure generation.** Diesel-exhaust exposures. Controlled exposures to dilute diesel exhaust were performed in purpose-built exposure chambers in Umeå, Sweden (Mills et al. 2005), and in Edinburgh, United Kingdom, through a collaboration with the National Institute for Public Health and the Environment (RIVM), the Netherlands, as described previously (Mills et al. 2011b). In Sweden, diesel exhaust was produced by a diesel engine (model TD45, 2.2 L, 500 rpm; Deutz, Cologne, Germany) and was diluted as above before being fed into a modified body-box exposure chamber (Mills et al. 2011b). The exposures were standardized with a target particulate matter mass concentration of 300 μg/m3. Participants were exposed to the diesel exhaust and filtered air for 1 hr during intermittent exercise on a bicycle to generate an average minute ventilation of 20 L/min/m2 body surface area.

**Wood-smoke exposures.** Wood smoke was generated using a common Nordic wood stove (chimney stove) in a controlled incomplete combustion firing procedure (Unosson et al. 2013). Birch wood logs with a moisture content of 16–18% were inserted every 5–15 min to maintain a high burn rate with repeated air-starved conditions. The wood smoke was diluted with filtered air (HEPA filter and activated carbon filter) in three steps and continuously fed into a controlled environment exposure chamber (15.3 m3) to achieve a steady-state concentration. The atmosphere in the chamber was monitored for gaseous pollutants using continuous measurement of NOx and CO. PM1 (particle matter with an aerodynamic diameter of ≤ 1 μm) mass concentration was measured on-line using a tapered element oscillating microbalance (TEOM 1400; Thermo Scientific, Waltham, MA, USA) equipped with a PM1 pre-cyclone. Integrated with the TEOM, a filter (Teflon) sampling line was used to determine the particle mass concentration gravimetrically. The exposures were standardized with a target PM1 mass concentration of 300 μg/m3 for 3 hr (n = 14) or 1,000 μg/m3 for 1 hr (n = 15). As before, participants were exposed to wood smoke during intermittent exercise to generate an average minute ventilation of 20 L/min/m2 body surface area.

**Ozone (O3–) exposures.** O3– was generated using an O3– generator (500 MM; Fischer Scientific, Schwerte, Germany) and the O3– concentration was measured continuously in the participant’s breathing zone using a photometric O3– analyzer (model 1108; Dasibi Environmental Corp., CA, USA). During the exposures, ambient air was continuously drawn through the chamber at a ventilation rate of 30 m3/hr (Blomberg et al. 1999). Temperature and relative humidity were maintained at 20°C and 50%, respectively. The exposures were standardized to an O3– concentration of 300 ppb for 75 min. Again participants performed intermittent exercise during the exposure to maintain an average minute ventilation of 20 L/min/m2 body surface area.

**Concentrated ambient particle (CAP) exposures.** A versatile aerosol concentration enrichment system (VACES) concentrator within a mobile ambient particle concentrator exposure laboratory sited outside the Royal Infirmary of Edinburgh (Edinburgh, UK), as used to deliver CAP exposures as described previously (Mills et al. 2008). Incoming ambient air (500 L/min) was saturated with water vapor to increase the size of ultrafine and fine particles before being passed through five parallel virtual impactors, each operating at 100 L/min. This increase in size, and therefore mass, ensured the particles had sufficient momentum to pass through the impactors, exiting in the minor flow (5 L/min) in which the particle concentration is enriched by a factor of 10 to 20-fold. The outward minor flow from the five impactors (25 L/min) was

---

Table 1. Baseline characteristics and medical history of participants included in studies.

| Parameter | Diesel exhaust | Wood smoke | O3– | CAPs | Engineered carbon NPs | Personal monitoring |
|-----------|----------------|-------------|-----|------|------------------------|-------------------|
| **Healthy volunteers** |                |             |     |      |                        |                   |
| No. of volunteers | 80 | 29 | 15 | 17 | 14 | 14 |
| Sex (male) | 74 (93) | 21 (72) | 15 (100) | 17 (100) | 14 (100) | 2 (14) |
| Age (years) | 25 (18–24) | 26 (20–35) | 25 (22–30) | 48 (21–69) | 21 (20–44) | 27 (20–45) |
| BMI (kg/m²) | 24 ± 3 | 25 ± 4 | NA | 25 ± 3 | 23 ± 2 | 21 ± 2 |
| Pulse (bpm) | 65 ± 12 | 62 ± 13 | 68 ± 13 | 63 ± 10 | 74 ± 8 | 79 ± 3 |
| SBP (mmHg) | 138 ± 17 | 122 ± 14 | 150 ± 15 | 138 ± 20 | 132 ± 12 | 113 ± 8 |
| DBP (mmHg) | 72 ± 9 | 72 ± 8 | 74 ± 8 | 77 ± 6 | 68 ± 8 | 73 ± 6 |
| Hemoglobin (g/dL) | 147 ± 11 | 146 ± 9 | 149 ± 9 | 144 ± 10 | 148 ± 11 | 119 ± 11 |
| Creatinine (μmol/L) | 76 ± 12 | 78 ± 20 | NA | NA | NA | NA |

| **Patients** |                |             |     |      |                        |                   |
| No. of patients | 37 | NA | NA | 12 | NA | 93 |
| Sex (male) | 33 (89) | NA | NA | 12 (100) | NA | 90 (86) |
| Age (years) | 63 (51–80) | NA | NA | 59 (45–68) | NA | 63 (45–77) |
| BMI (kg/m²) | 27 ± 3 | NA | NA | 28 ± 3 | NA | 26 ± 3 |
| Pulse (bpm) | 57 ± 8 | NA | NA | 53 ± 5 | NA | 67 ± 10 |
| SBP (mmHg) | 138 ± 20 | NA | NA | 138 ± 10 | NA | 131 ± 17 |
| DBP (mmHg) | 77 ± 8 | NA | NA | 80 ± 10 | NA | 79 ± 10 |
| Hemoglobin (g/dL) | 140 ± 11 | NA | NA | 148 ± 7 | NA | 142 ± 11 |
| Creatinine (μmol/L) | 78 ± 12 | NA | NA | 101 ± 12 | NA | 76 ± 16 |

| **Medical history** |                |             |     |      |                        |                   |
| Previous MI | 23 (62) | NA | NA | 7 (58) | NA | 68 (73) |
| Diabetes mellitus | 0 (0) | NA | NA | 0 (0) | NA | 43 (46) |
| Hypercholesterolemia | 25 (68) | NA | NA | 12 (100) | NA | 40 (43) |
| Hypertension | 8 (22) | NA | NA | 4 (33) | NA | 76 (81) |
| Angina pectoris | 14 (38) | NA | NA | 5 (42) | NA | 65 (70) |
| Medication use |                |             |     |      |                        |                   |
| Aspirin | 36 (97) | NA | NA | 12 (100) | NA | 87 (94) |
| Clopidogrel | 3 (8) | NA | NA | 0 (0) | NA | 16 (17) |
| Beta-blocker | 26 (70) | NA | NA | 11 (92) | NA | 67 (72) |
| Statin | 32 (87) | NA | NA | 12 (100) | NA | 73 (79) |
| ACE inhibitor | 13 (35) | NA | NA | 1 (8) | NA | 28 (30) |

Abbreviations: ACE, angiotensin-converting enzyme; BMI, body mass index; CAPs, concentrated ambient particles; DBP, diastolic blood pressure; MI, myocardial infarction; NA, not applicable; NPs, nanoparticles; SBP, systolic blood pressure. Values are expressed as n (%), mean ± SD, or median (IQR), as appropriate.
desaturated by silica gel dryers to restore
the particles to their original size, and diluted
with filtered air before delivery into the
human exposure chamber (50 L/min). Air
was sampled in the participant’s breathing
zone and analyzed continuously for tempera-
ture, humidity, particle mass concentration,
particle number concentration, NOx, CO,
sulfur dioxide (SO2), and O3– (Mills et al.
2008). Participants were exposed to CAPS at
a target concentration of 200 μg/m3 for 2 hr
during intermittent exercise to generate an
average minute ventilation of 20 L/min/m2
body surface area.

Exposure to engineered carbon nano-
particles (NPs). An aerosol of carbon NPs
was generated from graphite electrodes
using an electric spark discharge generator
(model CFG1000; Palas GmbH, Karlsruhe,
Germany) in an atmosphere of pure argon.
The output of the generator was mixed with
filtered air, passed through an impac-
tor with a cutoff of 0.1 μm, and fed into a
whole-body exposure chamber (Mills et al.
2011b). Participants were exposed to the car-
bon particles for 2 hr with a target exposure
of 4 × 106 particles/cm3 during intermittent
exercise to generate an average minute ventila-
tion of 20 L/min/m2 body surface area.

Ambient exposures and personal moni-
toring. On two occasions in two randomized
open-label controlled crossover studies, partici-
pants were randomized to wear no mask or a
highly efficient occupational facemask (Dust
Pants) for 2 hr with a target concentration of
diesel exhaust (Mills et al. 2011b) in controlled-exposure
studies and ambient air pollution (n = 107)
in Beijing, China (Langrish et al. 2009,
2012b) (Table 2). The mean recording time
was 22 ± 5 hr, and there were > 12,500 hr of
ECG data in total.

There was no difference between the
incidence of arrhythmias or the number of
arrhythmias (Table 3, Figure 1) in each
participant after any exposure as compared
with filtered air (or in the case of the ambient
exposures, an exposure in the presence of
a highly efficient facemask). Similarly,
there was no difference in the incidence or
number of arrhythmias in the healthy vol-
unteer and patient subgroups when analyzed
independently (see Supplemental Material,
Tables S1 and S2). One patient with coro-
nary artery disease (73-year-old male with a
past medical history of a previous myocardial
infarction and hypertension, with a baseline
blood pressure of 172/95 mmHg, who was
taking aspirin, benazepril, bisoprolol, and
simvastatin) had an asymptomatic episode of
nonsustained AF lasting 15 sec while walking
in central Beijing during his exposure visit
(without a facemask). There were no other
episodes of AF or flutter identified during the
> 12,500 hr of continuous ECGs.

Discussion
We have compiled the single largest series of
studies documenting continuous ECG moni-
toring in healthy volunteers and patients with
stable coronary heart disease on appropriate
medical therapy, who have been exposed to
a diverse range of environmental air pollut-
ants in acute controlled-exposure studies. In
> 12,500 hr of ECG data, we identified no
evidence to suggest an increased tendency to
arrhythmia after brief controlled exposures.
These data indicate that there is no significant

Table 2. Exposure parameters for air pollution exposures.

| Exposure (min) | Group | PM2.5 (μg/m3) | PM10 (μg/m3) | Particle count (× 104/cm3) | CO (ppm) | NOx (ppm) | NO (ppm) | NO2 (ppm) | O3– (ppm) | THC (ppm) |
|----------------|-------|---------------|--------------|-----------------------------|----------|-----------|----------|-----------|-----------|-----------|
| Diesel exhaust | 60 (n = 64) | HV | 307 | 79 | 6.57 | 4.08 | 4.45 | 1.10 | NA | 3.0 |
| 60 (n = 37) | Patients | NA | 294 | 103 | 3.82 | 3.29 | 2.46 | 0.83 | NA | 2.8 |
| 120 (n = 16) | HV | NA | 363 | 120 | 3.50 | 0.60 | 0.40 | 0.20 | NA | NA |
| Ambient (median) | 120 (n = 14) | HV | 98 | NA | 2.4 | NA | NA | NA | NA | NA |
| 120 (n = 93) | Patients | 98 | NA | 4.4 | NA | NA | NA | NA | NA | NA |
| Wood smoke | 60 (n = 15) | HV | 895 (PM1) | NA | NA | 15.32 | NA | 0.53 | NA | NA |
| 180 (n = 14) | HV | 314 (PM1) | NA | NA | 26.00 | 0.41 | NA | NA | NA | NA |
| O3– (n = 15) | HV | NA | NA | NA | NA | NA | NA | 0.30 | NA | NA |
| CAPs | 120 (n = 29) | HV & patients | 190 | 9.9 | 0.02 | 0.01 | 0.01 | 0.01 | NA | NA |
| Engineered carbon NPs | 120 (n = 14) | HV | 70 | 387 | NA | NA | NA | NA | NA | NA |

Abbreviations: HV, healthy volunteers; NA, not applicable; NO, nitric oxide; NO2, nitrogen dioxide; PM1 < 1 μm in aerodynamic diameter; PM10 ≤ 10 μm in aerodynamic diameter; THC, total hydrocarbons. Values are expressed as mean, except as noted.
risk of arrhythmia associated with controlled exposure to a wide range of air pollutants.

**Air pollution and risk of arrhythmia.** The epidemiological data linking exposure to air pollution and arrhythmia is limited. In a recent study conducted in Taipei, Taiwan, the total hospital admissions with cardiac arrhythmia over a 4-year period (> 16,000 hospital visits) were associated with daily increases in PM air pollution (Chiu et al. 2013), although the investigators provided no information on the type of arrhythmias observed. Among patients with implantable cardiac defibrillators, some studies have reported an increase in ventricular arrhythmias with increasing exposure to particulate air pollutants (Dockery et al. 2005; Ljungman et al. 2008; Peters et al. 2000; Rich et al. 2006). In a recent study of elderly patients with coronary heart disease, in which 20% of participants had a history of congestive cardiac failure, there was a small

| Exposure; arrhythmia | No. of participants with documented arrhythmia | OR (95% CI) | p-Value | No. of events per participant | median (IQR) | Unexposed | Exposed | p-Value |
|----------------------|-----------------------------------------------|-------------|---------|-------------------------------|--------------|-----------|---------|---------|
| Diesel exhaust (n = 117) | Pause 2 1 | 0.50 (0.04–5.55) | 0.56 | 0 (0–0) | 0 (0–0) | > 0.99 |
| | Dropped beat 2 36 37 | | 1.04 (0.60–1.81) | 0.89 | 0 (0–1) | 0 (0–1) | 0.72 |
| | VT 1 0 | 0.33 (0.01–8.20) | 0.32 | 0 (0–0) | 0 (0–0) | > 0.99 |
| | Salvo 1 4 | 4.11 (0.45–37.32) | 0.18 | 0 (0–0) | 0 (0–0) | 0.56 |
| | Triplet 1 3 | 3.05 (0.31–29.80) | 0.31 | 0 (0–0) | 0 (0–0) | > 0.99 |
| | Couplet 1 11 | 1.25 (0.50–3.13) | 0.64 | 0 (0–0) | 0 (0–0) | > 0.99 |
| | Bradycardia 60 57 | 0.90 (0.54–1.51) | 0.69 | 1 (0–57) | 0 (0–35.5) | 0.30 |
| | SVT 1 2 | 1.00 (0.14–7.22) | 1.00 | 0 (0–0) | 0 (0–0) | > 0.99 |
| | AF 0 0 | NA | NA | NA | NA | NA |
| | Bigeminy 7 3 | 0.41 (0.10–1.64) | 0.20 | 0 (0–0) | 0 (0–0) | 0.96 |
| | Trigeminy 4 4 | 1.00 (0.24–4.10) | 1.00 | 0 (0–0) | 0 (0–0) | 0.50 |
| | VE 58 54 | 0.87 (0.52–1.46) | 0.60 | 1 (0–4) | 0 (0–4.5) | 0.75 |
| | SVE 61 65 | 1.15 (0.69–1.92) | 0.60 | 1 (0–6) | 0 (0–4.5) | 0.90 |
| Ambient (n = 107) | Pause 0 0 | NA | NA | NA | NA | NA |
| | Dropped beat 1 2 | 2.02 (0.18–22.62) | 0.56 | 0 (0–0) | 0 (0–0) | > 0.99 |
| | VT 1 2 | 2.02 (0.18–22.62) | 0.56 | 0 (0–0) | 0 (0–0) | > 0.99 |
| | Salvo 1 2 | 2.02 (0.18–22.62) | 0.56 | 0 (0–0) | 0 (0–0) | > 0.99 |
| | Triplet 1 0 | 0.33 (0.01–8.20) | 0.32 | 0 (0–0) | 0 (0–0) | > 0.99 |
| | Couplet 9 4 | 0.42 (0.13–1.42) | 0.15 | 0 (0–0) | 0 (0–0) | 0.24 |
| | Bradycardia 25 21 | 0.8 (0.42–1.54) | 0.51 | 0 (0–0) | 0 (0–0) | 0.82 |
| | SVT 2 5 | 2.57 (0.49–13.57) | 0.25 | 0 (0–0) | 0 (0–0) | 0.45 |
| | AF 0 1 | 3.03 (0.12–75.34) | 0.32 | 0 (0–0) | 0 (0–0) | > 0.99 |
| | Bigeminy 16 18 | 1.15 (0.55–2.40) | 0.71 | 0 (0–0) | 0 (0–0) | 0.80 |
| | Trigeminy 4 5 | 1.26 (0.33–4.84) | 0.73 | 0 (0–0) | 0 (0–0) | 0.50 |
| | VE 87 86 | 0.94 (0.48–1.86) | 0.86 | 7 (1–66) | 7 (1–83) | 0.52 |
| | SVE 86 88 | 1.13 (0.57–2.25) | 0.73 | 5 (1–28) | 5 (1–28) | 0.25 |
| CAPs (n = 29) | Pause 1 0 | 0.32 (0.01–8.24) | 0.31 | 0 (0–0) | 0 (0–0) | > 0.99 |
| | Dropped beat 5 5 | 1.00 (0.26–3.91) | 1.00 | 0 (0–0) | 0 (0–0) | 0.73 |
| Wood smoke (n = 29) | VT 0 0 | NA | NA | NA | NA | NA |
| | Salvo 1 0 | 0.32 (0.01–8.24) | 0.31 | 0 (0–0) | 0 (0–0) | > 0.99 |
| | Triplet 2 4 | 2.16 (0.36–12.85) | 0.39 | 0 (0–0) | 0 (0–0) | > 0.99 |
| | Couplet 2 3 | 1.56 (0.24–10.10) | 0.64 | 0 (0–0) | 0 (0–0) | > 0.99 |
| | Bradycardia 16 14 | 0.76 (0.27–2.13) | 0.60 | 2 (0–33) | 0 (0–28.5) | 0.42 |
| | SVT 0 0 | NA | NA | NA | NA | NA |
| | AF 0 0 | NA | NA | NA | NA | NA |
| | Bigeminy 2 1 | 0.48 (0.04–5.64) | 0.55 | 0 (0–0) | 0 (0–0) | > 0.99 |
| | Trigeminy 1 2 | 2.07 (0.18–24.24) | 0.55 | 0 (0–0) | 0 (0–0) | > 0.99 |
| | VE 22 26 | 2.76 (0.64–11.96) | 0.16 | 5 (0.5–34.5) | 4 (2–28.5) | 0.93 |
| | SVE 23 23 | 1.00 (0.28–3.56) | 1.00 | 2 (1–8) | 4 (1–13) | 0.08 |

Table continued
increase in the risk of nonsustained ventricular tachycardia measured on ambulatory ECG with increasing exposure to PM air pollution (Bartell et al. 2013), although the same study did not find associations with changes in HRV or supraventricular arrhythmias. The finding of an increased risk of ventricular arrhythmia is, however, not consistent, and others have failed to show similar associations (Anderson et al. 2010; Metzger et al. 2007; Rich et al. 2004; Vedal et al. 2004). In a recent long-term follow-up from the Normative Aging Study, short-term exposure to combustion-derived PM air pollution (measured as black carbon) was associated with an increased risk of ventricular ectopy (Zanobetti et al. 2014). There is an association between air pollution exposure and the risk of hospitalization due to cardiac dysrhythmia (Colais et al. 2012; Santos et al. 2008; Tsai et al. 2009) and out-of-hospital cardiac arrest (Rosenthal et al. 2013), although this may be confounded by the strong association between exposure and the triggering of myocardial infarction (Nawrot et al. 2011) or decompensation of patients with cardiac failure (Atkinson et al. 2013; Shah et al. 2013).

Although air pollution exposure is robustly linked to changes in cardiac autonomic nervous system activity (Pieters et al. 2012), which in turn may alter atrial electrical properties and increase the risk of atrial arrhythmia (Arora 2012; Lo et al. 2011; Park et al. 2012), the association between air pollutant exposure and supraventricular arrhythmia is less robust. Among patients with coronary heart disease and elderly participants, increasing exposure to PM air pollution increased the incidence of asymptomatic runs of supraventricular arrhythmias.

**Table 3. Continued.**

| Exposure; arrhythmia | No. of participants with documented arrhythmia | OR (95% CI) | p-Value | No. of events per participant [median (IQR)] | p-Value |
|----------------------|-----------------------------------------------|-------------|---------|---------------------------------------------|---------|
|                      | Unexposed | Exposed |                      | Unexposed | Exposed |                      |         |
| Engineered carbon NPs (n = 14) |          |          |                      |          |          |                      |         |
| Pause                | 0         | 0        | NA                   | NA       | NA       | NA                   | NA       |
| Dropped beat         | 14        | 12       | 0.17 (0.01–3.94)     | 0.14     | 6 (2.75–14) | 6.5 (3.25–13.75)     | 0.88     |
| VT                   | 0         | 0        | NA                   | NA       | NA       | NA                   | NA       |
| Salvo                | 0         | 0        | NA                   | NA       | NA       | NA                   | NA       |
| Triplet              | 0         | 0        | NA                   | NA       | NA       | NA                   | NA       |
| Couplett             | 0         | 0        | NA                   | NA       | NA       | NA                   | NA       |
| Bradycardia          | 7         | 6        | 0.75 (0.17–3.32)     | 0.70     | 0.5 (0–64) | 0 (0–26)             | 0.74     |
| SVT                  | 0         | 0        | NA                   | NA       | NA       | NA                   | NA       |
| AF                   | 0         | 0        | NA                   | NA       | NA       | NA                   | NA       |
| Bigeminy             | 0         | 0        | NA                   | NA       | NA       | NA                   | NA       |
| Trigeminy            | 0         | 0        | NA                   | NA       | NA       | NA                   | NA       |
| VE                   | 7         | 9        | 1.80 (0.40–8.19)     | 0.45     | 0.5 (0–7.25) | 1 (0–5.5)          | 0.64     |
| SVE                  | 9         | 10       | 1.39 (0.28–6.84)     | 0.69     | 2.5 (0–5) | 2 (0–5)             | 0.42     |
| O3– (n = 15)         |          |          |                      |          |          |                      |         |
| Pause                | 1         | 1        | 1.00 (0.06–17.63)    | 1.00     | 0 (0–0) | 0 (0–0)             | > 0.99   |
| Dropped beat         | 5         | 8        | 2.29 (0.52–10.01)    | 0.27     | 0 (0–1) | 1 (0–4)             | 0.23     |
| VT                   | 0         | 0        | NA                   | NA       | NA       | NA                   | NA       |
| Salvo                | 0         | 0        | NA                   | NA       | NA       | NA                   | NA       |
| Triplet              | 0         | 0        | NA                   | NA       | NA       | NA                   | NA       |
| Couplett             | 0         | 0        | NA                   | NA       | NA       | NA                   | NA       |
| Bradycardia          | 12        | 11       | 0.69 (0.12–3.79)     | 0.67     | 18 (1–271) | 14 (0–33)           | 0.12     |
| SVT                  | 0         | 0        | NA                   | NA       | NA       | NA                   | NA       |
| AF                   | 0         | 0        | NA                   | NA       | NA       | NA                   | NA       |
| Bigeminy             | 0         | 0        | NA                   | NA       | NA       | NA                   | NA       |
| Trigeminy            | 0         | 0        | NA                   | NA       | NA       | NA                   | NA       |
| VE                   | 12        | 8        | 0.29 (0.06–1.44)     | 0.25     | 2 (1–3) | 1 (0–2)             | 0.21     |
| SVE                  | 9         | 12       | 2.67 (0.52–13.66)    | 0.23     | 1 (0–3) | 1 (1–3)             | 0.86     |

Abbreviations: NA, not applicable; SVE, supraventricular ectopic beat; SVT, supraventricular tachycardia including AF; VE, ventricular ectopic beat; VT, ventricular tachycardia. Bradycardia is defined as HR < 50 bpm. Data expressed as n or median (IQR), as appropriate. p-Values and ORs from chi-square analysis and Wilcoxon matched-pairs signed rank test, as appropriate.

**Figure 1.** Forest plots showing the risk of arrhythmias during and after exposure to air pollutants compared with a control air exposure (or in the presence of a highly efficient facemask for the ambient exposures). Abbreviations: SVE, supraventricular ectopy; SVT, supraventricular tachycardia; VE, ventricular ectopy; VT, ventricular tachycardia. p > 0.05 for all (chi-square analysis).
in two observational studies (Berger et al. 2006; Sarnat et al. 2006). However, in a recent robust case-crossover study of > 10,000 admissions to hospital with AF, there was no association with PM air pollution (Bunch et al. 2011). A more recent prospective analysis of patients with implantable cardiac defibrillators with established cardiac disease showed an increased risk of AF with acute increases in exposure to PM air pollution (Link et al. 2013). These contrasting findings may reflect the underlying individual susceptibility to arrhythmia of the patients recruited into the trials. Positive associations have generally been in patients with established cardiac disease, most notably cardiac failure who have structural abnormalities of the cardiac muscle and are generally at increased risk of developing cardiac dysrhythmias. Indeed, we have recently observed an increased risk of hospitalization and death with increasing PM air pollution exposure in patients with heart failure (Shah et al. 2013).

We previously reported that among 32 healthy volunteers and 20 patients exposed to dilute diesel exhaust in controlled-exposure studies, there were no increases in cardiac arrhythmia or changes in HRV (Mills et al. 2011a), and the findings from the present study are similar. Our screening procedures ensured all healthy volunteers were free from cardiac disease, and we excluded patients with coronary heart disease who had resting ECG abnormalities or a history of arrhythmia. Therefore, we studied a relatively low-risk population. We cannot exclude an effect of exposure to air pollutants in patients with overt cardiac failure who have conditional susceptibility to developing arrhythmias.

In their recent case report, Ghiotto et al. (2012) described a 58-year-old hypertensive female volunteer with frequent atrial ectopy who developed sustained AF/flutter during exposure to CAPs. The authors suggested a causal link; however, AF is the most common cardiac arrhythmia in the general population and is associated with increasing age, hypertension, and cardiac dysfunction and may be triggered by atrial ectopic beats originating from within the pulmonary veins (Haisaguerre et al. 1998). We suggest that it is more likely that the investigators simply witnessed an asymptomatic episode of AF in a patient at increased arrhythmic risk due to coexistent hypertension, age, and frequent atrial ectopy, and the occurrence of AF in the exposure chamber is likely to have been coincidental and simply due to chance. The short (< 0.25 min) single episode of symptomatic AF in > 750,000 min of ECG recordings in our studies is similarly likely to be due to chance in a patient at risk of arrhythmia due to poorly controlled hypertension and ischemic heart disease.

**Conclusions**

Our data suggest that acute controlled exposures to air pollutants are safe and do not significantly increase the short-term risk of arrhythmia among individuals at low risk of arrhythmia. Research employing these techniques, when scientifically and ethically justified (National Research Council 2004; Rom et al. 2013), should continue and remains crucial in identifying pathophysiological pathways involved in the adverse effects of air pollution, such as those with chronic respiratory conditions and coronary heart disease.

**References**

Anderson HR, Armstrong B, Hajat S, Harrison R, Monk V, Poloniecki J, et al. 2010. Air pollution and activation of implantable cardioverter defibrillators in London. Epidemiology 21(3):405–413.

Arora R. 2012. Recent insights into the role of the autonomic nervous system in the creation of substrate for atrial fibrillation: implications for therapies targeting the autonomic nervous system. Circ Arrhythm Electrophysiol 5(4):850–859.

Atkinson RW, Carey IM, Kent AJ, van Staa TP, Anderson HR, Cook DG. 2013. Long-term exposure to outdoor air pollution and incidence of cardiovascular diseases. Epidemiology 24(1):44–53.

Barath S, Mills NL, Lundbäck M, Törnvist H, Lucking A, Langrish JP, et al. 2010. Impaired vascular function after exposure to diesel exhaust generated at urban transient running conditions. Part Fibre Toxicol 7:19; doi:10.1186/1743-8977-7-19.

Bartell SM, Longhurst J, Tjoa T, Sioutas C, Delfino RJ. 2013. Particulate air pollution, ambulatory heart rate variability, and cardiac arrhythmia in retirement community residents with coronary artery disease. Environ Health Perspect 121:1135–1141; doi:10.1289/ehp.1205914.

Berger A, Zareba W, Schneider A, Ruckerl R, Ilbärd-Mulli A, Cyrys J, et al. 2008. Runs of ventricular and supraventricular tachycardia triggered by air pollution in patients with coronary heart disease. J Occup Environ Med 50(11):1149–1158.

Blumberg A, Mudway IS, Nordenhall C, Hedenstrom H, Kelly FJ, Frew AJ, et al. 1999. Ozone-induced lung function decrements do not correlate with early airway inflammatory or oxidative stress responses. Eur Respir J 13(5):1018–1026.

Brook RD, Rajagopalan S, Pope CA III, Brook JR, Bhatnagar A, Diez-Roux AV, et al. 2010. Particulate matter air pollution and cardiovascular disease, an update to the scientific statement from the American Heart Association. Circulation 121:2331–2378.

Bunch TJ, Horne BD, Asirvatham SJ, Day JD, Crandall BG, Weiss JP, et al. 2011. Atrial fibrillation hospitalization is not increased with short-term elevations in exposure to fine particulate air pollution. Pacing Clin Electrophysiol 34(11):1475–1479.

Chiu HF, Tsai SS, Weng HH, Yang CY. 2013. Short-term effects of fine particulate air pollution on emergency room visits for cardiac arrhythmias: a case-crossover study in Taipei. J Toxicol Environ Health A 76(10):614–623.

Colaiz P, Faustini A, Stafoggia M, Bent G, Bisanti L, Cadem U, et al. 2012. Particulate air pollution and hospital admissions for cardiac diseases in potentially sensitive subgroups. Epidemiology 23(3):473–481.

Cruts B, van Etten L, Törnvist H, Blomberg A, Sandström T, Mills NL, et al. 2008. Exposure to diesel exhaust induces changes in EEG in human volunteers. Part Fibre Toxicol 5:4; doi:10.1186/1743-8977-5-4.

Dockery DW, Lutzmann-Gibson H, Rich DG, Link MS, Schwartz JD, Gold DR, et al. 2005. Particulate air pollution and nonfatal cardiac events within 30 minutes of air pollution with confirmed arrhythmias recorded by implanted defibrillators. Res Rep Health Eff Inst 124:38–126.

Ghiotto AJ, Bassett M, Montilla T, Chung EH, Smith CB, Causio VE, et al. 2012. Case report: supraventricular arrhythmia after exposure to concentrated ambient air pollution particles. Environ Health Perspect 127:275–277; doi:10.1289/ehp.1103877.

Gold DR, Mittelman MA. 2013. New insights into pollution and the cardiovascular system: 2010 to 2012. Circulation 127(18):1903–1913.

Haisaguerre M, Jais P, Shah DC, Takahashi A, Hocini M, Quiniou G, et al. 1998. Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. N Engl J Med 339(10):569–566.

Langrish JP, Bosson J, Unosson J, Muula A, Newby DE, Mills NL, et al. 2012a. Cardiovascular effects of particulate air pollution exposure: time course and underlying mechanisms. J Intern Med 272(3):224–239.

Langrish JP, Frampton M, Blomberg A. 2010. Human exposure studies. In: Cardiovascular Effects of Inhaled Ultrafine and Nanosized Particles (Cassee F, Mills N, Newby D, eds). Hoboken, NJ:J Wiley & Sons, 217–239.

Langrish JP, Li X, Wang S, Lee MM, Barnes GD, Miller MR, et al. 2012b. Reducing personal exposure to particulate air pollution improves cardiovascular health in patients with coronary heart disease. Environ Health Perspect 120:367–372; doi:10.1289/ehp.1103878.

Langrish JP, Mills NL, Chan JK, Leesman DL, Aitken RJ, Fokkens PH, et al. 2008. Beneficial cardiovascular effects of reducing exposure to particulate air pollution with a simple facemask. Part Fibre Toxicol 6:8; doi:10.1186/1743-8977-6-8.

Link MS, Lutzmann-Gibson H, Schwartz J, Mittelman MA, Wesseler B, Gold DR, et al. 2013. Acute exposure to air pollution triggers atrial fibrillation. J Am Coll Cardiol 62(9):816–825.

Ljungman PL, Berglind N, Holmgnen C, Gadler F, Edvardsson N, Pershagen G, et al. 2008. Rapid effects of air pollution on ventricular arrhythmias. Eur Heart J 29(23):2894–2901.

Lo LW, Chiou CW, Lin YJ, Lee SH, Chen SA. 2011. Neural mechanism of atrial fibrillation: insight from global high density frequency mapping. J Cardiovasc Electrophysiol 22(9):1048–1056.

Metzger KB, Klein M, Flanders WD, Peel JL, Mulholland JA, Langberg JJ, et al. 2009. Environmental effects from taxi pollution and ventricular arrhythmias. Eur Heart J 29(23):2894–2901.

Mills NL, Finlayson AE, Gonzalez MC, Törnvist H, Barath S, Mills NL, et al. 2012b. Reducing personal exposure to particulate air pollution improves cardiovascular health in patients with coronary heart disease. Environ Health Perspect 120:367–372; doi:10.1289/ehp.1103878.

Mills NL, Chan JK, Leesman DL, Aitken RJ, Fokkens PH, et al. 2008. Beneficial cardiovascular effects of reducing exposure to particulate air pollution with a simple facemask. Part Fibre Toxicol 6:8; doi:10.1186/1743-8977-6-8.

Link MS, Lutzmann-Gibson H, Schwartz J, Mittelman MA, Wesseler B, Gold DR, et al. 2013. Acute exposure to air pollution triggers atrial fibrillation. J Am Coll Cardiol 62(9):816–825.

Ljungman PL, Berglind N, Holmgren C, Gadler F, Edvardsson N, Pershagen G, et al. 2008. Rapid effects of air pollution on ventricular arrhythmias. Eur Heart J 29(23):2894–2901.
Mills NL, Robinson SD, Fokkens PH, Leseman DL, Miller MR, Anderson D, et al. 2008. Exposure to concentrated ambient particles does not affect vascular function in patients with coronary heart disease. Environ Health Perspect 116:709–715; doi:10.1289/ehp.11016.

Mills N, Törnvist H, Gonzales M, Vink E, Robinson S, Söderberg S, et al. 2007. Ischemic and thrombotic effects of dilute diesel-exhaust inhalation in men with coronary heart disease. N Engl J Med 357(11):1075–1082.

Mills N, Törnvist H, Robinson S, Gonzales M, Darnley K, MacNee W, et al. 2005. Diesel exhaust inhalation causes vascular dysfunction and impaired endogenous fibrinolysis. Circulation 112:3930–3936.

National Research Council. 2004. Research Priorities for Airborne Particulate Matter: IV. Continuing Research Progress. Washington, DC:National Academies Press.

Nawrot TS, Perez L, Künzli N, Munters E, Nemery B. 2011. Public health importance of triggers of myocardial infarction: a comparative risk assessment. Lancet 377(9767):732–740.

Odemuyiwa O, Malik M, Farrell T, Bashir Y, Poloniecki J, Camm J. 1991. Comparison of the predictive characteristics of heart rate variability index and left ventricular ejection fraction for all-cause mortality, arrhythmic events and sudden death after acute myocardial infarction. Am J Cardiol 68(5):434–439.

Peters A, Liu E, Verrier RL, Schwartz J, Gold DR, Mittleman M, et al. 2000. Air pollution and incidence of cardiac arrhythmia. Epidemiology 11(1):11–17.

Pietera N, Plusquin M, Cox B, Kicinski M, Vangronsveld J, Navrots T. 2012. An epidemiological appraisal of the association between heart rate variability and particulate air pollution: a meta-analysis. Heart 98(15):1127–1135.

Rich DG, Kim MH, Turner JR, Mittleman MA, Schwartz J, Catalano PJ, et al. 2006. Association of ventricular arrhythmias detected by implantable cardioverter defibrillator and ambient air pollutants in the St Louis, Missouri metropolitan area. Occup Environ Med 63(9):591–596.

Rich KE, Petkau J, Vedal S, Brauer M. 2004. A case-crossover analysis of particulate air pollution and cardiac arrhythmia in patients with implantable cardioverter defibrillators. Inhal Toxicol 16(6–7):363–372.

Rom WN, Boushey H, Caplan A. 2013. Experimental human exposure to air pollutants is essential to understand adverse health effects. Am J Respir Cell Mol Biol 49(5):691–696.

Rosenthal FS, Kuisma M, Lanki T, Hussein T, Boyd J, Halonen JI, et al. 2013. Association of ozone and particulate air pollution with in-hospital cardiac arrest in Helsinki, Finland: evidence for two different etiologies. J Expo Sci Environ Epidemiol 23(3):281–288.

Santos UP, Terra-Filho M, Lin CA, Pereira LA, Vieira TC, Saldiva PH, et al. 2008. Cardiac arrhythmia emergency room visits and environmental air pollution in Sao Paulo, Brazil. J Epidemiol Community Health 62(3):267–272.

Sarnat SE, Suh HH, Coulil BA, Schwartz J, Stone PH, Gold DR. 2006. Ambient particulate air pollution and cardiac arrhythmia in a panel of older adults in Steubenville, Ohio. Occup Environ Med 63(10):700–706.

Shah A, Langrish J, Nair H, McMullist D, Hunter A, Donaldson K, et al. 2013. Global association of air pollution and heart failure: a systematic review and meta-analysis. Lancet 382(9897):1039–1046.

Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. 1996. Heart rate variability: standards of measurement, physiological interpretation and clinical use. Circulation 93(5):1043–1065.

Tsai SS, Chiu HF, Wu TN, Yang CY. 2009. Air pollution and emergency room visits for cardiac arrhythmia in a subtropical city: Taipei, Taiwan. Inhal Toxicol 21(13):1113–1118.

Unosson J, Blomberg A, Sandstrom T, Muala A, Boman C, Nystrom R, et al. 2013. Exposure to wood smoke increases arterial stiffness and decreases heart rate variability in humans. Part Fibre Toxicol 10(1):20. doi:10.1186/1743-8977-10-20.

Vedal S, Rich K, Brauer M, White R, Petkau J. 2004. Air pollution and cardiac arrhythmias in patients with implantable cardioverter defibrillators. Inhal Toxicol 16(6–7):353–362.

Zanobetti A, Coulil BA, Gryparis A, Klock I, Sparrow D, Vokonas PS, et al. 2014. Associations between arrhythmia episodes and temporality and spatially resolved black carbon and particulate matter in elderly patients. Occup Environ Med 71(3):201–207.